Imaging and Pathology Correlations for Different Risk Stratification Models for Intermediate-risk Prostate Cancer

Anticancer Res. 2017 Mar;37(3):1237-1242. doi: 10.21873/anticanres.11439.

Abstract

Background/aim: We evaluated whether sub-stratifying intermediate-risk (IR) prostate cancer using the Memorial Sloan Kettering Cancer (MSKCC) or Prostate Cancer Risk Stratification (ProCaRS) model predicts for adverse imaging or pathologic features.

Patients and methods: 56 consecutive IR patients who underwent multi-parametric MRI (mpMRI) and radical prostatectomy (RP) were studied. The different groups were tested for correlation with adverse findings. 2-sample T-tests assuming unequal variance were used.

Results: On mpMRI the MSKCC unfavorable group had higher index lesion suspicion scores (p=0.044), while the ProCaRS model showed a higher maximum tumor diameter (MTD) in the high-risk group (p=0.047). At RP, a higher pathologic MTD (23.3 vs. 17.6 mm, p=0.005) was present in the MSKCC unfavorable group as well as the ProCaRS high vs. low group (26.6 vs. 19.3 mm, p=0.022).

Conclusion: Both models demonstrated a correlation with higher MTD for unfavorable IR patients. This is likely a driver of worse clinical outcomes.

Keywords: MSKCC; ProCars; maximal tumor diameter; mpMRI; prostatectomy.

MeSH terms

  • Adult
  • Aged
  • Biopsy
  • Diffusion
  • Humans
  • Magnetic Resonance Imaging
  • Male
  • Medical Oncology / methods*
  • Medical Oncology / standards
  • Middle Aged
  • Neoplasm Recurrence, Local / pathology
  • Neoplasm Staging
  • Patient Selection
  • Prognosis
  • Prostate / pathology
  • Prostate-Specific Antigen / blood
  • Prostatectomy
  • Prostatic Neoplasms / diagnostic imaging*
  • Prostatic Neoplasms / physiopathology*
  • Retrospective Studies
  • Risk Assessment
  • Treatment Outcome

Substances

  • Prostate-Specific Antigen